Page last updated: 2024-12-07
2-hydroxyethylvaline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-hydroxyethylvaline: RN given refers to (DL)-isomer; RN for cpd without isomeric designation not available 11/88 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 107912 |
SCHEMBL ID | 3294007 |
MeSH ID | M0160741 |
Synonyms (11)
Synonym |
---|
2-hydroxyethylvaline |
n-2-(hydroxyethyl)-l-valine |
FT-0669626 |
21768-51-4 |
n-(2-hydroxyethyl)valine |
dl-valine, n-(2-hydroxyethyl)- |
SCHEMBL3294007 |
2-(2-hydroxyethylamino)-3-methylbutyric acid, 97% (cp) |
n-2-(hydroxyethyl)-l-valine-d4(technical grade) |
FT-0669627 |
n-(2-hydroxyethyl)-dl-valine |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" By analyzing published data on ethylene oxide in man its half-life was estimated to be 42 min." | ( Pharmacokinetics of ethylene in man; body burden with ethylene oxide and hydroxyethylation of hemoglobin due to endogenous and environmental ethylene. Denk, B; Ehrenberg, L; Filser, JG; Kessler, W; Törnqvist, M, 1992) | 0.28 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" A novel method using gas chromatography-mass spectrometry (GC-MS) has been used to monitor the presence of this adduct in smokers and control subjects, and dose-response relationships were investigated between HOEtVal in haemoglobin, number of cigarettes smoked per day and plasma cotinine levels." | ( 2-Hydroxyethylation of haemoglobin in man. Bailey, E; Brooks, AG; Farmer, PB; Passingham, BJ; Yates, DW, 1988) | 0.27 |
" The dose-response curves for 7-HEG in rat tissues were linear between 10 and 100 ppm ETO and increased in slope above 100 ppm." | ( Molecular dosimetry of DNA and hemoglobin adducts in mice and rats exposed to ethylene oxide. Fennell, TR; MacNeela, JP; Swenberg, JA; Upton, PB; Walker, VE, 1993) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (35)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (14.29) | 18.7374 |
1990's | 17 (48.57) | 18.2507 |
2000's | 7 (20.00) | 29.6817 |
2010's | 4 (11.43) | 24.3611 |
2020's | 2 (5.71) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.10
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.10) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (2.56%) | 5.53% |
Reviews | 4 (10.26%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 34 (87.18%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |